ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2006) 11 P242

Soluble interleukin 2 receptor is elevated in sera of women with Graves’ disease and has relation to serum free thyroxin and thyroid volume

J Jiskra1, M Antosova1, E Potlukova1, Z Lacinova1, H Mareckova2, P Sandova2, D Smutek1 & Z Limanova1

13rd Medical Department of the 1st Medical Faculty, Charles University, Prague, Czech Republic; 2Laboratory of Clinical Immunology, General Faculty Hospital, Prague, Czech Republic.

Introduction: Although some studies have shown elevated soluble interleukin 2 receptor (sIL-2R) in sera of patients with hematological malignancies and some autoimmune diseases, its role in serum is not fully understood.

Patients and methods: The aim was to compare serum levels of sIL-2R in four groups of women (11 with Graves’ disease, 10 with Hashimoto’s thyroiditis, 11 with breast cancer and 10 healthy controls) and to test their possible relationship to parameters of thyroid function (TSH, FT4), thyroid antibodies (against thyroid peroxidase-TPOAb, thyroglobulin-TgAb and TSH receptor-TRAK) and thyroid volume. Serum levels of sIL-2R were measured using a commercially available ELISA kit, the other parameters using routine laboratory methods. All subjects underwent thyroid ultrasonography (Phillips Envisor) with measurement of thyroid volume.

Results: Serum levels of sIL-2R were significantly higher in women with Graves‘ disease compared to Hashimoto’s thyroiditis (1.46±0.50 vs. 0.833±0.184 ng/ml, P<0.001), breast cancer (1.46±0.50 vs. 0.91±0.51, P=0.021) and controls (1.46±0.50 vs. 0.81±0.21, P=0.016). In the whole group, strong positive correlations between sIL-2R and FT4 (r=0.688, P=0.00000357, n=42) and sIL-2R and thyroid volume (r=0.636, P=0.000363, n=42) were found. No significant correlations were found between sIL-2R and TPOAb, TgAb and TRAK.

Conclusions: The close relation of sIL-2R to FT4 suggests that serum sIL-2R is rather the consequence of changes of thyroid function than thyroid autoimmunity. In contrast to hematological malignancies, sIL-2R was not elevated in sera of women with breast cancer.

Supported by grant IGANR8130-3.

Article tools

My recent searches

No recent searches.